Company
Headquarters: Pinkenba, QLD, Australia
Employees: 73
CEO: Mr. Richard Carreon
A$145.8 Million
AUD as of July 1, 2024
US$97.1 Million
Company | Market Cap (USD) |
---|---|
Abbott | $178.02 B |
Stryker Corporation | $126.48 B |
Boston Scientific Corporation | $112.32 B |
Medtronic | $98.95 B |
Edwards Lifesciences Corporation | $55.63 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was incorporated in 1999 and is headquartered in Pinkenba, Australia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
ImpediMed Limited has the following listings and related stock indices.
Stock: ASX: IPD wb_incandescent
Stock: OTC: IPDQF wb_incandescent